Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model.
about
Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectivePharmacokinetics and pharmacodynamics of antifungals in children: clinical implicationsIn vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and CandidaFluconazole dosing for the prevention or treatment of invasive candidiasis in young infantsPopulation pharmacokinetics of fluconazole in young infants.Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infectionOne year prospective survey of Candida bloodstream infections in Scotland.Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia.Correspondence of in vitro and in vivo fluconazole dose-response curves for Cryptococcus neoformans.Antifungal susceptibility testing of fluconazole by flow cytometry correlates with clinical outcome.Antifungal susceptibility testing: practical aspects and current challenges.In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model.Evaluation of voriconazole pharmacodynamics using time-kill methodologyPharmacokinetics-pharmacodynamics of a sordarin derivative (GM 237354) in a murine model of lethal candidiasisNovel entries in a fungal biofilm matrix encyclopediaEfficacy and pharmacodynamics of flucytosine monotherapy in a nonneutropenic murine model of invasive aspergillosis.Time course of microbiologic outcome and gene expression in Candida albicans during and following in vitro and in vivo exposure to fluconazole.Rat indwelling urinary catheter model of Candida albicans biofilm infection.Clinical validation of the analysis of fluconazole in oral fluid in hospitalized children.Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testingImpact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans.In vivo fluconazole pharmacodynamics and resistance development in a previously susceptible Candida albicans population examined by microbiologic and transcriptional profilingFluconazole loading dose pharmacokinetics and safety in infantsIn vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model.In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model.Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasisIn vivo pharmacodynamics of antifungal drugs in treatment of candidiasis.Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model.Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia.Antifungal pharmacokinetics and pharmacodynamicsFluconazole population pharmacokinetics and dosing for prevention and treatment of invasive Candidiasis in children supported with extracorporeal membrane oxygenation.Nontoxic antimicrobials that evade drug resistance.Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.Commentary: pediatric antifungal drug development: lessons learned and recommendations for the future.In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemiaThe Ssk1p response regulator and Chk1p histidine kinase mutants of Candida albicans are hypersensitive to fluconazole and voriconazole.Host contributions to construction of three device-associated Candida albicans biofilmsOptimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.
P2860
Q27009221-B6C5BC7C-9391-4675-89AB-1EB2EA1E6FCBQ27025299-B8FCA59B-30C3-40E1-927E-9D80C7EE69A3Q28344464-65239C97-29D4-486F-B784-E8C51147F31AQ30435365-CF1C6A13-17EC-464F-9D75-A8820D6E8702Q30439710-59DA6357-826B-4F35-A3AA-9C6065594947Q33768787-7B1B9193-ED1D-47B9-8B0A-F7E57A310CC2Q33910250-8491D541-77D7-4FE5-BB1F-37326D6DC9CEQ33938082-9F6C6ADC-0744-4698-B13F-1CCBD000E870Q33938166-BD61B5FF-7AD2-4C0B-817B-A3FF175A2128Q33972828-FEBCE22D-2435-43F9-BE01-A5CBF1375340Q33975757-6D9CCF92-C5EC-4DD8-BCE0-2FB29EB51868Q33979115-826CD3D1-ECFD-49D0-8C9F-9F4D2AA0B760Q33980062-6055CE91-87F6-467B-9836-592A9FD71AA2Q33980421-6F1FF11F-F098-454C-BE73-3238AF455384Q34026267-4BB43E42-34E0-4F92-ACFA-A5F6AA7D7684Q34077069-D99E94C7-4545-4608-9BD4-13EA9D553AE4Q34510556-192169DD-FB1D-48D0-8F97-BDF56BD03796Q34595925-9ACBD73D-2D63-4FDE-837E-AF0C4DBF2D5FQ34597018-D6C94686-5FB5-47E7-9FAB-9D520E6B198EQ34647337-1029B970-F944-46D6-B055-5E7BFF6B9C0FQ34721695-8B9DDB1B-A4D2-45B6-BBC3-8BC30B10D298Q34721706-5DED4948-0704-4E38-BE17-1A8651E95F47Q34807770-9F5E71E6-C166-4BC1-BCEB-DFED0E23A7B8Q34881309-F2A3EFA3-000A-43C0-90BB-F635A80932BDQ34881676-A25FFE3A-1C7E-4A75-9CB8-711A3EAE3F4CQ35007030-BE60383B-8358-4CBE-A5D1-C3DB72A33437Q35091285-8C5E9C20-1A9F-443B-A923-8B6BBFBC5122Q35105763-A57B738D-DDD2-42F0-B32F-F3828A3DF756Q35635693-59283B92-D778-42D7-A2D5-7809A04291FDQ35663841-41727EF3-20FE-4EBE-98D4-D2A44457A41EQ35746253-6EAD46F0-E97A-4D46-A65E-AFFA518F2F1EQ35756422-95275FAB-4910-471B-A56E-26FE3C88DA5CQ35912756-F93F0507-62E2-4F73-B21C-964C831A2EC2Q35973357-FDD6469D-369A-491C-9D81-BFA6B651375CQ36048229-E384F381-890E-4EFA-B0A8-57EA58028212Q36094974-D00ACA8F-6C2A-46E1-B676-B4B3AB0682F6Q36095050-D85E3B90-9174-44D1-961B-51B99C9AEFB5Q36281368-2FBCC29A-75C2-49D5-8E1A-78DB55C83E24Q36364100-49F85C57-1DFA-4968-85A5-BA0026598E75Q36425025-C18BB76F-5E79-473A-BD08-01197FCFB927
P2860
Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Characterization and quantitat ...... d candidiasis infection model.
@ast
Characterization and quantitat ...... d candidiasis infection model.
@en
type
label
Characterization and quantitat ...... d candidiasis infection model.
@ast
Characterization and quantitat ...... d candidiasis infection model.
@en
prefLabel
Characterization and quantitat ...... d candidiasis infection model.
@ast
Characterization and quantitat ...... d candidiasis infection model.
@en
P2860
P1476
Characterization and quantitat ...... d candidiasis infection model.
@en
P2093
P2860
P304
P407
P577
1999-09-01T00:00:00Z